<DOC>
	<DOCNO>NCT00989196</DOCNO>
	<brief_summary>This clinical study investigate pharmacokinetics , efficacy , safety immunogenicity human-cl rhFVIII , newly develop human cell-line derive recombinant FVIII concentrate previously treat patient severe Hemophilia A .</brief_summary>
	<brief_title>Clinical Study Investigate Pharmacokinetics , Efficacy , Safety Immunogenicity Recombinant FVIII Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A ( FVIII : C &lt; = 1 % ) Male subject 12 65 year age Body weight 25 kg 110 kg Previously treat FVIII concentrate least 150 EDs Other coagulation disorder hemophilia A Present past FVIII inhibitor activity</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>